Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.
To study the toxicity profile and effectiveness of combination of trastuzumab and docetaxel in women with metastatic breast cancer showing HER-2 overexpression (IHC 3+). Sixteen women with metastatic breast cancer were treated with trastuzumab (2 mg/kg every week) and docetaxel (100 mg/m2) as first-line therapy. A loading dose of 4 mg/kg trastuzumab was given on week 1. We planned to give a minimum of six cycles of docetaxel chemotherapy. A total of 89 cycles of docetaxel chemotherapy was given (median five cycles per patient). Median number of cycles of trastuzumab was 44 with a range of 20-71. Of the 16 patients, seven (44%) had complete response (CR), whereas five patients (31%) had partial response (PR). The overall response rate (CR+PR) was 75%. Two patients died of progressive disease, and the other two died at home, for which the cause of death could not be known. No anaphylaxis, cardio-toxicity or febrile neutropenia was observed in any patient. Overall, the toxicity was within tolerable limits. The combination of trastuzumab and docetaxel in women with metastatic breast cancer showing HER-2 overexpression (IHC 3+) is a safe and effective regimen. However, further randomised trials are needed to establish its role in metastatic breast cancer.